Loading...
Loading...
Exelixis, Inc.
EXEL today announced that it has initiated
CELESTIAL, a phase 3 pivotal trial comparing cabozantinib with placebo
in patients with advanced hepatocellular carcinoma (HCC) who have
previously been treated with sorafenib. The primary endpoint for the
trial is overall survival (OS).
“Patients with advanced HCC who have progressed on sorafenib have few
therapeutic options, and new approaches to managing their disease are
much needed,” said Ghassan K. Abou-Alfa, M.D., Associate Attending at
Memorial Sloan-Kettering Cancer Center, New York and the lead
investigator on CELESTIAL. “Phase 2 data investigating cabozantinib in
this patient population are worthy of more study, and cabozantinib's
target profile, which includes inhibition of both MET and VEGFR,
See full press release© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in